Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

8 Questions with Darius Moshfeghi.

Busbee BG.

Ophthalmic Surg Lasers Imaging Retina. 2017 Jul 1;48(7):602-604. doi: 10.3928/23258160-20170630-15. No abstract available.

PMID:
28728190
2.

CD44 deletion leading to attenuation of experimental autoimmune encephalomyelitis results from alterations in gut microbiome in mice.

Chitrala KN, Guan H, Singh NP, Busbee B, Gandy A, Mehrpouya-Bahrami P, Ganewatta MS, Tang C, Chatterjee S, Nagarkatti P, Nagarkatti M.

Eur J Immunol. 2017 Jul;47(7):1188-1199. doi: 10.1002/eji.201646792. Epub 2017 Jun 6.

PMID:
28543188
3.

Reply: To PMID 24246824.

Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.

Ophthalmology. 2015 Nov;122(11):e70-1. No abstract available.

PMID:
26798857
4.

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9.

5.

Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2016 Apr;123(4):858-64. doi: 10.1016/j.ophtha.2015.11.030. Epub 2016 Jan 8.

6.

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group.

Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034. Epub 2015 Dec 8.

7.

Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.

Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z.

Am J Ophthalmol. 2015 Nov;160(5):1014-1023.e2. doi: 10.1016/j.ajo.2015.07.034. Epub 2015 Jul 29.

8.

Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2015 Sep;122(9):1846-53.e5. doi: 10.1016/j.ophtha.2015.05.042. Epub 2015 Jul 2.

9.

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group.

Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11.

10.

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2014 Nov;121(11):2181-92. doi: 10.1016/j.ophtha.2014.05.009. Epub 2014 Jul 9.

11.

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.

Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2014 Oct;121(10):1956-65. doi: 10.1016/j.ophtha.2014.04.020. Epub 2014 May 15.

12.

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group.

Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. doi: 10.1016/j.ajo.2014.04.004. Epub 2014 Apr 13.

13.

Our advances are fabulous. Then what is the problem?

Brown GC, Busbee BG.

Curr Opin Ophthalmol. 2014 May;25(3):155-7. doi: 10.1097/ICU.0000000000000053. No abstract available.

PMID:
24675285
14.

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group.

JAMA Ophthalmol. 2014 May;132(5):521-7.

15.

Cataract surgery cost utility revisited in 2012: a new economic paradigm.

Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.

Ophthalmology. 2013 Dec;120(12):2367-76. doi: 10.1016/j.ophtha.2013.04.030.

PMID:
24246824
16.

The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.

Singh UP, Singh NP, Guan H, Busbee B, Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M, Nagarkatti PS.

Int Rev Immunol. 2014 Jan;33(1):23-33. doi: 10.3109/08830185.2013.809071. Epub 2013 Jul 10. Review.

17.

Leptin antagonist ameliorates chronic colitis in IL-10⁻/⁻ mice.

Singh UP, Singh NP, Guan H, Busbee B, Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M, Nagarkatti PS.

Immunobiology. 2013 Dec;218(12):1439-51. doi: 10.1016/j.imbio.2013.04.020. Epub 2013 May 13.

18.

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1.

19.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.

20.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

Supplemental Content

Loading ...
Support Center